Del Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
FDA denies firm's request for a six-month extension of June 18 effective date of the final rule requiring all OTC ophthalmic anti-infectives to be removed from the market. In response to the final rule published last December, Del decided to reformulate its Stye ophthalmic ointment by dropping yellow mercuric oxide 1% and adding mineral oil and petrolatum. Del had asked FDA for an extension to allow sufficient time to reformulate and relabel the product ("The Tan Sheet" April 19, p. 11)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning